Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know

• Applications for targeted therapy in gynecologic cancers are growing rapidly.
• Resistance to targeted therapy may be innate, acquired, or adaptive.
• Translational endpoints will be essential to maximize response to targeted therapy.

Precision medicine is a rapidly evolving area in the treatment of gynecologic malignancies. Advances in sequencing technology have resulted in an increasing wealth of data regarding the genomic characteristics of ovarian, endometrial, and cervical cancers. These vast new datasets of information have led to novel insights into potential vulnerabilities and therapeutic targets for these cancers. However, unraveling the complex molecular changes within cancer cells to determine how best to attack these targets and to identify effective biomarkers of response remains a significant challenge. In this article, we review the current status of biomarker-driven targeted therapy in gynecologic malignancies.